Adherence and persistence to Rivaroxaban, Dabigatran, and vitamin K antagonist in patients with atrial fibrillation for stroke risk reduction

Trial Profile

Adherence and persistence to Rivaroxaban, Dabigatran, and vitamin K antagonist in patients with atrial fibrillation for stroke risk reduction

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Dabigatran etexilate
  • Indications Atrial fibrillation; Stroke
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top